GRAIL (NASDAQ:GRAL) CFO Aaron Freidin Sells 655 Shares

GRAIL, Inc. (NASDAQ:GRAL) CFO Aaron Freidin sold 655 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $53.01, for a total value of $34,721.55. Following the sale, the chief financial officer owned 308,967 shares in the company, valued at $16,378,340.67. The trade was a 0.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Aaron Freidin also recently made the following trade(s):

• On Monday, March 9th, Aaron Freidin sold 2,492 shares of GRAIL stock. The shares were sold at an average price of $47.89, for a total value of $119,341.88.
• On Monday, March 2nd, Aaron Freidin sold 9,573 shares of GRAIL stock. The stock was sold at an average price of $50.17, for a total value of $480,277.41.

GRAIL Stock Down 0.8%

NASDAQ:GRAL opened at $49.82 on Tuesday. GRAIL, Inc. has a twelve month low of $20.44 and a twelve month high of $118.84. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -4.46 and a beta of 5.21. The stock’s 50 day moving average price is $88.14 and its two-hundred day moving average price is $77.99.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings data on Thursday, February 19th. The company reported ($2.44) EPS for the quarter, beating the consensus estimate of ($3.33) by $0.89. GRAIL had a negative return on equity of 17.58% and a negative net margin of 277.46%.The company had revenue of $43.60 million during the quarter, compared to the consensus estimate of $43.33 million. As a group, analysts anticipate that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on GRAL shares. Morgan Stanley cut their price target on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 24th. Guggenheim upped their target price on shares of GRAIL from $100.00 to $130.00 and gave the company a “buy” rating in a report on Monday, January 26th. TD Cowen initiated coverage on shares of GRAIL in a research note on Thursday, February 19th. They issued a “hold” rating and a $114.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Finally, Robert W. Baird set a $82.00 price target on GRAIL in a research report on Friday, February 20th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $90.17.

Key Stories Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Negative Sentiment: CEO Robert P. Ragusa sold 7,461 shares on March 9 at an average $47.89 (~$357,307), cutting his position by ~1.15%. SEC Filing
• Negative Sentiment: CEO Robert P. Ragusa sold 980 shares on March 5 at $53.01 (~$51,950), a ~0.15% reduction in his stake. SEC Filing
• Negative Sentiment: President Joshua J. Ofman sold 2,937 shares on March 9 at $47.89 (~$140,653), trimming his holding by ~0.67%. SEC Filing
• Negative Sentiment: President Joshua J. Ofman sold 690 shares on March 5 at $53.01 (~$36,577), a ~0.16% reduction in his stake. SEC Filing
• Negative Sentiment: CFO Aaron Freidin sold 2,492 shares on March 9 at $47.89 (~$119,342), reducing his position by ~0.81%. SEC Filing
• Negative Sentiment: CFO Aaron Freidin sold 655 shares on March 5 at $53.01 (~$34,722), a ~0.21% reduction in his holding. SEC Filing

Institutional Investors Weigh In On GRAIL

Several hedge funds have recently added to or reduced their stakes in GRAL. N.E.W. Advisory Services LLC bought a new position in GRAIL during the fourth quarter worth $26,000. Comerica Bank raised its position in shares of GRAIL by 59.2% in the third quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of GRAIL during the 4th quarter worth about $28,000. Elyxium Wealth LLC acquired a new stake in shares of GRAIL during the 4th quarter worth about $31,000. Finally, Intesa Sanpaolo S.p.A. bought a new stake in shares of GRAIL during the 4th quarter worth about $44,000.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.